HTA_DM.pdf

More documents

Recommendations

Info

RIESGO DE EVENTOS CVMUNDThe 18th FIFA Soccer World Cup 2006 in GermanyEjercicio en partidos: catecolaminas.Jugadores: juego real de 90min = 60min consume 1500cal.Referi: 79min.Ejercicio regular protege, vigoroso deletéreo.Emonional: Público-hinchas: penales y tiempo extracatecolaminas: PA, FC, Tako-subo miocardiop. HiperG sin comer.European Heart Journal Adv Acc publ October 16, 2006 (Alemania)Dr. Lavandaio 2010.
RIESGO DE EVENTOS CVMUNDThe 18th FIFA Soccer World Cup 2006 in GermanyFIFA World Cup in France in 1998, emergency admissions foracute myocardial infarction were increased in England for 2 daysafter the penalty elimination of England against Argentina (Table1).1 mort IAM y MS. IDEM 2002.European Heart Journal Adv Acc publ October 16, 2006 (Alemania)Dr. Lavandaio 2010.
Page 6 and 7: RIESGO DE EVENTOS CVMUND(FIFA) Worl
Page 8 and 9: Presente
Page 10 and 11: PREVALENCIA DE HTAEN 6 PAÍSES DE E
Page 12 and 13: Pasado
Page 14 and 15: Sodio y Potasio - Hipertensión Art
Page 16 and 17: Sodio y Potasio - Hipertensión Art
Page 18 and 19: Devising New Drugs for the Treatmen
Page 20 and 21: JNC 7The Seventh Report of the Join
Page 22 and 23: JNC 7: HTAImportancia del control d
Page 24 and 25: JNC 7: HTATratamiento: Metas: BPLTT
Page 26 and 27: CHEP 2010Adultos 1 de 5 en Canadá
Page 28 and 29: CHEP 2010Riesgo de HTA en normotens
Page 30 and 31: HTA - MORTALIDADHTA MORT: Coron/eda
Page 32 and 33: HTA - REDUCCIÓNMORT - CVEvent - CV
Page 34 and 35: PATOGENIAPATOGAnn Intern Med. 2003;
Page 36 and 37: Genética:PATOGENIAPATOGCandidato g
Page 38 and 39: Sistema nervioso simpático:PATOGEN
Page 40 and 41: Reactividad vascular:PATOGENIAPATOG
Page 42 and 43: PATOGENIAPATOGEnfermedad renal micr
Page 44 and 45: Rigidez arterial:PATOGENIAPATOGLa P
Page 46 and 47: PATOGENIAPATOGRigidez: La mayoría
Page 48 and 49: Curva J:ACVCONTROVERSIAPATOGIAMJ. A
Page 50 and 51: PATOGENIASistema renina-angiotensin
Page 52 and 53:
PATOGENIASistema renina-angiotensin
Page 54 and 55:
Aldosterona:PATOGENIAPATOGExtraadre
Page 56 and 57:
Bloqueo dual IECA + ARB:PATOGENIAPA
Page 58 and 59:
PATOGANTIHIPERTENSIVOS - DIABETES p
Page 60 and 61:
Mecanismos:PATOGANTIHIPERTENSIVOS -
Page 62 and 63:
PATOGANTIHIPERTENSIVOS - DIABETES p
Page 64 and 65:
TRIALSDr. Lavandaio 2010.
Page 66 and 67:
TRIALSALLHAT The Antihypertensive a
Page 68 and 69:
TRIALSHOT Effects of intensive bloo
Page 70 and 71:
TRIALSLIFE Cardiovascular morbidity
Page 72 and 73:
TRIALSONTARGET Telmisartan, Ramipri
Page 74 and 75:
TRIALSAVOID Aliskiren Combined with
Page 76 and 77:
TRIALSAliskiren Renal Effects of Al
Page 78 and 79:
TRIALSACCORD Rationale and Design f
Page 80 and 81:
TRIALSNAVIGATOR Effect of Nateglini
Page 82 and 83:
Toma de Presión arterialPreparaci
Page 84 and 85:
Toma de Presión arterialPreparaci
Page 86 and 87:
CHEP 2010 ALGORITMOPA elevada alaza
Page 88 and 89:
HTA ENMASCARADAMAPA casa o amb PAS
Page 90 and 91:
UMBRAL DE TRATAMIENTOCondiciónHTA
Page 92 and 93:
CAUSAS MODIFICABLESMedicación:AINE
Page 94 and 95:
SCORE 10 year Fatal CardiovascularR
Page 96 and 97:
RIESGO a 10 años UKPDS - DMUKPDS R
Page 98 and 99:
DESAFÍOSEl 44% de la gente no pued
Page 100 and 101:
HTA 2° ALDOSTERONISMOHipokalemia e
Page 102 and 103:
European Society of HypertensionCla
Page 104 and 105:
ESTILO DE VIDA PREV/TRATReducir ing
Page 106 and 107:
REDUCCIÓN DE Na BENEFICIOReducció
Page 108 and 109:
REDUCCIÓN DE Na BENEFICIOReducció
Page 110 and 111:
JNC 7: HTAAlgoritmo de tratamiento
Page 112 and 113:
TRATAMIENTO FÁRMACOSAdulto con HTA
Page 114 and 115:
TRATAMIENTO FÁRMACOSAgregar en HTA
Page 116 and 117:
Incremenal SBP reduction ratioObser
Page 118 and 119:
TRATAMIENTO FÁRMACOSHTA con DMMeta
Page 120 and 121:
Standards of Medical Care in Diabet
Page 122 and 123:
Standards of Medical Care in Diabet
Page 124 and 125:
ANTIHIPERTENSIVOS - PARADOJACONTROL
Page 126 and 127:
ANTIHIPERTENSIVOS - PARADOJACONTROL
Page 128 and 129:
CONCLUSIONESConocer la PA de los pa
show all

HTA_DM.pdf

Create successful ePaper yourself

Delete template?

Save as template?